Why Gilead Sciences, Inc. (NASDAQ:GILD) Is A Good Buy For Long Term Investors?

1781
Gilead Sciences, Inc

The investors who had a chance to pounce on the opportunity of purchasing Gilead Sciences, Inc. (NASDAQ:GILD), are probably enjoying almost thrice the amount that they started off with. For those investors who are willing to park their cash at a profitable position in a biotech company, here is why Gilead Sciences can be your best bet.

HIV program of Gilead Sciences

The company enjoyed early limelight through the HIV program. Gilead Sciences is known to be the leader in this segment and has some of the much acclaimed therapies and treatments for the same in market. Complera/Eviplera, Stribild, Atripla and Truvada are just to name a few. The company has only recently enhanced its product line in HIV, with new addition to the compay’s portfolip. The newer commercial products joining the earlier ones include Odefsey, Descovey and Genvoya.

Growth guaranteed through hepatitis C virus franchise

The company experienced tremendous growth from its HCV or hepatitis C virus franchise. The whopping revenue of Gilead Sciences can be attributed to the enormous sales of Harvoni and Sovaldi. Epclusa is the latest addition to the HCV drug product line and this too, is making a name for itself.

Despite facing a tougher competition from the peer, the company emerges as a winner; especially when it comes to giving a tougher fight.

Why Gilead Sciences presents a solid case for investment?

Albeit there is a tough competition and everything comes at a certain price, but it wouldn’t be wrong to say that Gilead Sciences still offers a blockbuster case for the investments. While the dominance of this company in HIV market continues, it is also swelling the portfolio for other indications.

The company, at present, has at least three drugs in the experimental stage and Gilead Sciences is looking for oncology portfolio enhancement as well. In fact, the company, only recently announced that it would be spending about $31.6 billion cash, cash equivalent or marketable securities on the cancer related drugs’ acquisitions.

Higher dividends and more buybacks is what this company rewards its shareholders with. So, for the investors looking for long term cash parking, Gilead Sciences is indeed the safest and profitable bet.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.